Free Trial
NASDAQ:BCAB

BioAtla (BCAB) Stock Price, News & Analysis

BioAtla logo
$0.42 -0.03 (-6.00%)
Closing price 04:00 PM Eastern
Extended Trading
$0.44 +0.02 (+5.71%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About BioAtla Stock (NASDAQ:BCAB)

Key Stats

Today's Range
$0.42
$0.46
50-Day Range
$0.33
$0.45
52-Week Range
$0.24
$2.53
Volume
528,990 shs
Average Volume
562,594 shs
Market Capitalization
$24.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Hold

Company Overview

BioAtla Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

BCAB MarketRank™: 

BioAtla scored higher than 49% of companies evaluated by MarketBeat, and ranked 582nd out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioAtla has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    BioAtla has only been the subject of 2 research reports in the past 90 days.

  • Read more about BioAtla's stock forecast and price target.
  • Percentage of Shares Shorted

    7.56% of the float of BioAtla has been sold short.
  • Short Interest Ratio / Days to Cover

    BioAtla has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in BioAtla has recently decreased by 7.76%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    BioAtla does not currently pay a dividend.

  • Dividend Growth

    BioAtla does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.56% of the float of BioAtla has been sold short.
  • Short Interest Ratio / Days to Cover

    BioAtla has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in BioAtla has recently decreased by 7.76%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    BioAtla has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for BioAtla this week, compared to 1 article on an average week.
  • Search Interest

    Only 5 people have searched for BCAB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added BioAtla to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioAtla insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.22% of the stock of BioAtla is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    77.23% of the stock of BioAtla is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about BioAtla's insider trading history.
Receive BCAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BCAB Stock News Headlines

BioAtla (NASDAQ:BCAB) Stock Price Up 1.4% - Here's What Happened
JMP Securities Downgrades BioAtla (BCAB)
Altucher: It Looks Like My Trump prediction is coming true
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.tc pixel
BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript
See More Headlines

BCAB Stock Analysis - Frequently Asked Questions

BioAtla's stock was trading at $0.5912 on January 1st, 2025. Since then, BCAB shares have decreased by 29.0% and is now trading at $0.42.

BioAtla, Inc. (NASDAQ:BCAB) released its quarterly earnings data on Thursday, August, 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by $0.02.
Read the conference call transcript
.

BioAtla (BCAB) raised $150 million in an initial public offering (IPO) on Wednesday, December 16th 2020. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG acted as the underwriters for the IPO.

Top institutional shareholders of BioAtla include Acorn Capital Advisors LLC (8.28%). Insiders that own company stock include Jay M Phd Short, Christian Vasquez, Lawrence Steinman and Sylvia Mcbrinn.
View institutional ownership trends
.

Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioAtla investors own include NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Visa (V).

Company Calendar

Last Earnings
8/07/2025
Today
8/28/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BCAB
CIK
1826892
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

High Price Target
$5.00
Low Price Target
$5.00
Potential Upside/Downside
+1,090.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$69.78 million
Net Margins
N/A
Pretax Margin
-541.04%
Return on Equity
-1,177.18%
Return on Assets
-137.51%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.24
Quick Ratio
1.24

Sales & Book Value

Annual Sales
$11 million
Price / Sales
2.24
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.29) per share
Price / Book
-1.45

Miscellaneous

Outstanding Shares
58,720,000
Free Float
52,133,000
Market Cap
$24.66 million
Optionable
Optionable
Beta
0.90

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:BCAB) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners